Marinus' Oral Ganaxolone Lowers Seizure Frequency In Genetic Disorder

  • Marinus Pharmaceuticals Inc MRNS announced topline data from its open-label Phase 2 trial evaluating oral ganaxolone in patients with seizures associated with tuberous sclerosis complex (TSC).
  • The primary endpoint showed a median 16.6% reduction in seizure frequency, with 30.4% of patients achieving a 50% or more seizure reduction. 
  • Patients with focal seizures (n=19) showed a median 25.2% reduction in focal seizure frequency during the trial.
  • Meaningful 50% responder rates were observed in subgroups of highly refractory seizure patients on concomitant medications cannabidiol (n=12) or everolimus (n=11).
  • Ganaxolone was generally well-tolerated though one treatment-related serious adverse event of seizure was reported.
  • RelatedMarinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion.
  • A global Phase 3 trial of adjunctive ganaxolone in approximately 160 TSC patients will start enrollment during Q4 2021. 
  • The primary endpoint is the percent change in 28-day TSC-associated seizure frequency.
  • The FDA granted orphan drug designation to ganaxolone for treatment in TSC. 
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: MRNS shares closed 0.74% at $12.04 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefstuberous sclerosis complex
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!